We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Robotic Technology Unveiled for Automated Diagnostic Blood Draws

By LabMedica International staff writers
Posted on 03 Feb 2026

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience. More...

To help address this challenge, Vitestro (Utrecht, Netherlands), a pioneer in medical robotics for automated diagnostic blood collection, has developed Aletta, the world’s first Autonomous Robotic Phlebotomy Device (ARPD), creating a new standard for how blood draws are performed.

Aletta is designed to autonomously perform routine diagnostic blood collection. The system integrates multimodal imaging, advanced robotics, and artificial intelligence to identify suitable veins, guide needle insertion, and collect blood samples with precision and consistency. Aletta is intended to support phlebotomy departments by addressing staffing constraints, reducing operator‑dependent variability, and standardizing specimen quality while enhancing patient experience.

The new website provides detailed information about Vitestro and its Aletta system, outlining the technology, intended diagnostic applications, and role in modern clinical laboratory and outpatient care settings. The site also features Vitestro’s newly released public video, which walks viewers through each step of the Aletta blood draw process, from arm placement at the device to completion of the procedure. The video offers a practical view of autonomous blood collection in routine clinical settings and marks the first time Vitestro has publicly shared a detailed visual explanation of the technology and its clinical workflow.

Aletta is currently CE marked and is available for clinical use in Europe. Vitestro is pursuing U.S. regulatory authorization alongside broader global expansion, with the goal of advancing autonomous diagnostic blood collection globally.

"Our new website and public video reflect a deliberate step toward more open communication and education,” said Toon Overbeeke, Chief Executive Officer of Vitestro. “As we bring autonomous robotic phlebotomy into routine clinical practice, it is essential that healthcare professionals and patients clearly understand how the technology works and how it integrates into real world care delivery. By making our technology and clinical workflow more visible, we are enabling informed adoption, building confidence, and supporting the responsible establishment of a new standard for diagnostic blood collection.”

Related Links
VItestro


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
POC Immunoassay Analyzer
Procise DX
New
Silver Member
Vitamin D Assay
EZ Vitamin D Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The AidaBREAST assay integrates multimodal data to provide patient-specific 10-year recurrence risk and individualized predictions of radiation therapy benefit (photo courtesy of PreludeDx)

Validated Test Predicts Recurrence Risk and Radiation Benefit in Early-Stage Breast Cancer

For women with early-stage invasive breast cancer who undergo breast-conserving surgery, clinicians must assess both the risk of locoregional recurrence and the potential benefit of adjuvant radiation therapy.... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Industry

view channel
Image: Natera\'s MCED assay analyzes cell-free DNA in blood to screen for multiple cancers (Image Credit: Adobe Stock)

Multi-Cancer Screening Blood Test Gains FDA Breakthrough Designation

Natera Inc.’s (Austin, TX, USA) multi-cancer early detection (MCED) assay has received Breakthrough Device designation (BDD) from the U.S. Food and Drug Administration (FDA). The assay analyzes cell-free... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.